The complexity of medical cannabis stems from the millions of combinations of doses and cannabinoid/terpene profiles. Despite this challenge, a systematic and intelligent approach can lead to informed recommendations that most benefit patients. Over time as more research is gathered, these recommendations will become progressively more robust, leading to higher levels of satisfaction with the first recommendation.
More importantly, modulating the activity of the endocannabinoid system turned out to hold therapeutic promise in a wide range of disparate diseases and pathological conditions, ranging from mood and anxiety disorders, movement disorders such as Parkinson’s and Huntington’s disease, neuropathic pain, multiple sclerosis and spinal cord injury, to cancer, atherosclerosis, myocardial infarction, stroke, hypertension, glaucoma, obesity/metabolic syndrome, and osteoporosis, to name just a few.
Wording taken From: 85R1145 GCB-F By: Menéndez S.B. No. 269 A BILL TO BE ENTITLED AN ACT (A)….. (The following information cites at least 2 related Scientific or Medical journals as resources citing topics specifically related to the “qualifying” disease, syndrome, or disability. ) cancer, Cannabinoids as therapeutic agents in cancer: current status and future… read more »
Article Outline Narrative review Historical perspective Terminology Cellular drug actions Disputed antiepileptic effects Causal agent in psychosis Cannabis use and cognitive impairment Cannabis use worsens neuropsychologic function in people with multiple sclerosis Cannabis-associated subcortical nuclear gray matter structural changes—neuroimaging Safety concerns Patient Description Discussion Cannabis-associated neuropathology Correlates of cannabis-associated microstructural white matter pathology Is the… read more »
Amy M. Cohn, Amanda L. Johnson, Shyanika W. Rose, Jessica M. Rath & Andrea C. Villanti Pages 203-213 | Published online: 19 Oct 2016 ABSTRACT Background: As of 2015, more than half of U.S. states have legalized, medicalized, or decriminalized marijuana. Objective: This study examined the prevalence and correlates of support for marijuana legalization in… read more »
Liting Deng, Lindsay Ng, Tatsuya Ozawa and Nephi Stella Journal of Pharmacology and Experimental Therapeutics November 7, 2016, jpet.116.236968; DOI: https://doi.org/10.1124/jpet.116.236968 Abstract Evidence suggests that the non-psychotropic cannabis-derived compound, cannabidiol (CBD), has anti-neoplastic activity in multiple types of cancers, including glioblastoma multiforme (GBM). DNA-damaging agents remain the main standard of care treatment available for patients… read more »
Pisanti S1, Malfitano AM2, Ciaglia E2, Lamberti A2, Ranieri R2, Cuomo G2, Abate M2, Faggiana G2, Proto MC3, Fiore D3, Laezza C4, Bifulco M5. Author information 1Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Italy. Electronic address: firstname.lastname@example.org. 2Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Italy…. read more »
Luciano De Petrocellis, Vittorio Vellani, Aniello Schiano-Moriello, Pietro Marini, Pier Cosimo Magherini, Pierangelo Orlando and Vincenzo Di Marzo Journal of Pharmacology and Experimental Therapeutics June 2008, 325 (3) 1007-1015; DOI: https://doi.org/10.1124/jpet.107.134809 Abstract The plant cannabinoids (phytocannabinoids), cannabidiol (CBD), and Δ9-tetrahydrocannabinol (THC) were previously shown to activate transient receptor potential channels of both vanilloid type 1… read more »
Elliott DA1, Nabavizadeh N2, Romer JL2, Chen Y3, Holland JM2. 1Department of Radiation Medicine, Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR, 97239, USA. email@example.com. 2Department of Radiation Medicine, Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR, 97239, USA…. read more »